Showing 141-150 of 3173 results for "".
- And the Winners Are...Mary Kay, ESDR Announce New Grant Recipientshttps://practicaldermatology.com/news/and-the-winners-are-mary-kay-esdr-announce-new-grant-recipients/2461724/Mary Kay Inc. and European Society for Dermatological Research announced their inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees. The $20,000 grants were to be awarded to two researchers working to uncover new perspectives and invention strategies. The two grant awardees are: …
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development as a once-daily, steroid-free, and cosm…
- Positive Results Seen for Alphyn’s AB-101 in Kids with ADhttps://practicaldermatology.com/news/positive-pediatric-results-seen-for-alphyns-ab-101-in-ad/2461700/Alphyn Biologics’ AB-101a performed well in a Phase 2a clinical trial of mild-to-moderate atopic dermatitis (AD), according to research presented at the 22nd European Society for Pediatric Dermatology Congress. Based on the positive trial results, Alphyn intends to initiate a multinational Phase …
- Kerecis Introduces Fish-Skin Graft and Silicone Cover for Wound Treatmenthttps://practicaldermatology.com/news/kerecis-introduces-fish-skin-graft-and-silicone-cover-for-wound-treatment/2461686/Kerecis rolled out MariGen Shield, a treatment which integrates the company’s fish-skin graft with a silicone contact layer for treating chronic and complex wounds. The company also announced the results of a clinical study comparing the effectiveness of the Kerecis fish-skin grafts to a standard …
- Green Living Environments Don't Protect Kids from Eczemahttps://practicaldermatology.com/news/green-living-environments-dont-protect-kids-from-eczema/2461675/Greenness or the significant presence of living vegetation around the home in early childhood does not seem to protect children from atopic eczema, a new Finnish study shows. Instead, the proximity of coniferous, mixed forests and agricultural areas was associated with elevated risk of eczema, espe…
- Skin Cancer Foundation Hits the Road: Destination Healthy Skin Program Kicks Off on May 6, 2023https://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road-destination-healthy-skin-program-kicks-off-on-may-6-2023/2461669/The Skin Cancer Foundation will launch its annual mobile education and screening program, Destination Healthy Skin, on Saturday, May 6, in Greenwich, Connecticut. The program educates the public about the importance of skin cancer early detection and effective sun protection. Inside the Destinati…
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in New York, NY, USA. He also serves as …
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting. At…
- Phase 3 Data: Dermavant's VTAMA Cream Performs Well in Adults and Kids with ADhttps://practicaldermatology.com/news/dermavant-vtama-cream-in-adults-and-kids-with-ad/2461612/Dermavant’s VTAMA (tapinarof) performed well in kids as young as 2 and adults with atopic dermatitis, according to topline results from the ADORING 2 Atopic Dermatitis Phase 3 Trial. VTAMA cream is a novel, aryl hydrocarbon receptor agonist, in development as a once-daily, steroid-free, and cosme…
- Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne and Androgenetic Alopeciahttps://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/Kintor Pharmaceutical Limited’s GT20029 was safe and well tolerated and had good pharmacokinetic characteristics in healthy people and people with androgenetic alopecia (AGA) or acne, according to a phase 1 clinical trial. GT20029 is the first topical PROTAC compound in the world that has complete…